Trial Profile
Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Aug 2015 New trial record